Clinical trials: Bone Tumour
Bone Neoplasm of Hip (Diagnosis), Orthopedic Disorder
Evaluation of the Ability of CT-based Finite Element Analysis (CTFEA) to Predict Fractures in Patients With Metastases: a Randomized Controlled Study.
Patients with metastases to proximal femur, who are evaluated fr the risk of pathologic fracture in order to decide on preventive fixation vs follow-up constitute the study population. The patients will be randomized in two arms.
- Conditions
- Bone Neoplasm of Hip (Diagnosis), Orthopedic Disorder, Bone Metastases, Proximal Femoral Metaphyseal Abnormality
- Trial name
- ZYCTFEA (NCT03453905)
- Testing
- CTFEA, Conventional decision algorithm
- Volunteers
- 162 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
This is an open-label, non-randomized, Phase 1 study to determine the safety and tolerability of NC525. This study will also assess the clinical benefit in subjects with advanced myeloid neoplasms.
- Conditions
- Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia, Relapsed or Refractory Myelodysplastic Syndrome
- Trial name
- NCT05787496
- Testing
- NC525
- Where
- 11 sites in United States
- Volunteers
- 28 people
- Sponsor
- NextCure, Inc.
Graft Versus Host Disease, Leukemia
Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD
RATIONALE: Allogeneic hematopoietic stem cell transplant (HSCT) is a treatment that can cure acute leukemia and myelodysplasia. After giving the patient chemotherapy and total body irradiation to stop the growth of cancer and…
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00914940
- Testing
- Fludarabine Phosphate, Tacrolimus, Thiotepa
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Fred Hutchinson Cancer Center
Recipients of Allogeneic Stem Cell Transplantation, HPV (Human Papillomavirus)-Associated
Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation
Patients who undergo allogeneic stem cell transplantation lose previously acquired immunity and are routinely revaccinated against many infectious diseases.
- Conditions
- Recipients of Allogeneic Stem Cell Transplantation, HPV (Human Papillomavirus)-Associated, Acute Myeloid Leukaemia, Myelodysplastic Syndrome
- Trial name
- NCT06793410
- Testing
- Early start post-transplant vaccination with Gardasil 9®, Late post-transplant vaccination with Gardasil 9®
- Where
- 5 sites in Sweden
- Volunteers
- 100 people
- Sponsor
- Vastra Gotaland Region
Multiple Myeloma, Newly Diagnosed
Clinical Implication of Bone Marrow Perfusion Patterns Imaged by Dynamic MRI in Multiple Myeloma
Background: Multiple myeloma (MM) is a clonal plasma cell neoplasm characterized by proliferation of neoplastic plasma cells in bone marrow (BM).
- Trial name
- NCT00166855
- Testing
- dynamic MRI and bone marrow sampling
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia
Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia
The purpose of this study is to find out the highest safe dose and examine the side effects and effectiveness of eltrombopag olamine in patients with acute myeloid leukemia (AML) treated with chemotherapy that have not responded…
- Conditions
- Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Trial name
- NCT01550185
- Testing
- eltrombopag olamine, standard follow-up care
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Roswell Park Cancer Institute
Multiple Myeloma and Malignant Plasma Cell Neoplasms
Comparable Investigation of One Fraction Radiotherapy and Multifraction Radiotherapy in Patients With Multiple Myeloma.
Radiotherapy is required to overcome pain and to evoke recalcification in multiple myeloma (MM) patients. Approximately 70% of all MM patients receive one or more radiotherapies in the course of their illness.
- Trial name
- NCT02024815
- Testing
- External Beam radiotherapy
- Where
- Lithuania
- Volunteers
- 100 people
- Sponsor
- Lithuanian University of Health Sciences
Hematologic Malignancy
Observational Study in Patients Who Underwent an Haploidentical Transplantation With T-repleted Bone Marrow
Outcome evaluation in patients who underwent transplantation with T-repleted bone marrow after post-transplantation cyclophosphamide
- Trial name
- NCT02049424
- Where
- Italy
- Volunteers
- 9 people
- Sponsor
- Istituto Clinico Humanitas
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, in Relapsed or Refractory
A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies
This study will evaluate the long-term safety of ARD103 cellular therapies
- Conditions
- Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, in Relapsed or Refractory, MDS (Myelodysplastic Syndrome)
- Trial name
- NCT06906380
- Testing
- Non interventional study
- Where
- 3 sites in United States
- Volunteers
- 49 people
- Sponsor
- ARCE Therapeutics, Inc.
Sarcoma, Childhood Osteosarcoma
Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas
RAD3CAR is a phase I study designed to evaluatethe safety of B7-H3-CAR T cells and lymphodepletion in combination with hypofractionated radiation therapy.
- Conditions
- Sarcoma, Childhood Osteosarcoma, Childhood Rhabdomyosarcoma, Childhood Soft Tissue Sarcoma
- Trial name
- NCT07222735
- Testing
- Fludarabine, Cyclophosphamide, B7-H3-CAR T Cells
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- St. Jude Children's Research Hospital
Odontogenic Cysts, Odontogenic Tumors
Evaluation of the Expression and Prognostic Role of Tumor Stem Cell Marker SOX2 in Odontogenic Cysts and Tumors
The pathogenesis of odontogenic lesions remains unclear; however, a probable explanation may involve the existence of tumor stem cells (TSCs), which are thought to generate both benign and malignant tumors.
- Trial name
- NCT06833840
- Where
- Egypt
- Volunteers
- 45 people
- Sponsor
- Mansoura University
Cancer
Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections
RATIONALE: White blood cells that have been treated in the laboratory may kill cells that are infected with cytomegalovirus. PURPOSE: This phase I trial is studying how well cytotoxic T cells work in treating patients who have…
- Trial name
- NCT00769613
- Testing
- cytomegalovirus IE-1-specific cytotoxic T lymphocytes, cytomegalovirus pp65-specific cytotoxic T lymphocytes, therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Milton S. Hershey Medical Center
Polycythemia Vera
A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera
This clinical trial is a Phase 2/3 study that will determine the recommended dose and dose regimen of AG-236 and evaluate the efficacy, safety, and pharmacokinetics of AG-236 in polycythemia vera (PV) by testing how well AG-236…
- Trial name
- PreVail (NCT07859423)
- Testing
- AG-236
- Volunteers
- 245 people
- Sponsor
- Agios Pharmaceuticals, Inc.
Myelodysplastic Syndrome, Acute Myelogenous Leukemia
Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
The goal of this clinical research study is to find out if decitabine, given with or without valproic acid, can help to control AML or MDS. The safety of both treatments will also be studied.
- Trial name
- NCT00414310
- Testing
- Decitabine, Valproic Acid
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- M.D. Anderson Cancer Center
Osteosarcoma Metastatic, Pulmonary Disease
Osteosarcoma With Resectable Pulmonary Metastasis: A Retrospective Study
According to EURAMOS-1, 17% of osteosarcoma patients were considered to have metastases at diagnosis. In this selected cohort, the reported 5-year EFS from diagnosis of 28% compares well to previous results reported from…
- Conditions
- Osteosarcoma Metastatic, Pulmonary Disease, Resectable Sarcoma, Survival
- Trial name
- NCT04546243
- Testing
- resection group, radiotherapy group
- Where
- 2 sites in China
- Volunteers
- 127 people
- Sponsor
- Peking University People's Hospital
Myelodysplastic Syndromes, Leukemia, Myeloid, Acute
A Study to Analyze the Occurrence of Transformation From Myelodysplastic Syndrome to Acute Myeloid Leukemia in Patients With Myelodysplastic Syndrome Who Received Revlimid® 5 mg Capsules and Who Are Continuing or no Longer Continuing Revlimid Treatment
To analyze the occurrence of transformation from myelodysplastic syndrome (MDS) to acute myeloid leukemia (hereinafter referred to as transformation from MDS to AML) in patients with myelodysplastic syndrome with a deletion 5q…
- Trial name
- NCT02921815
- Where
- Japan
- Volunteers
- 84 people
- Sponsor
- Celgene
Chronic Myeloid Leukemia (CML) With Philadelphia Chromosome-positive (Ph+)
Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+)
The purpose of this study is to evaluate the hematological, cytogenetic and molecular response to continuous-use of Imatinib in children with CML Ph+.
- Trial name
- NCT01221376
- Testing
- Imatinib Mesylate
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Renato Melaragno
Acute Myeloid Leukemia, Juvenile Myelomonocytic Leukemia
Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML
The addition of gemtuzumab ozogamicin (GO) in combination with Busulfan/Cyclophosphamide followed by AlloSCT in patients with high risk CD33+ AML/JMML/MDS will be safe and well tolerated.
- Conditions
- Acute Myeloid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome
- Trial name
- High Risk (NCT00669890)
- Testing
- Gemtuzumab Ozogamicin, Busulfan, Cyclophosphamide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- New York Medical College
Breast Cancer, Leukemia
High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors
RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00060255
- Testing
- busulfan, carboplatin, carmustine
- Where
- United States
- Volunteers
- 451 people
- Sponsor
- Roswell Park Cancer Institute
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelomonocytic Leukemia
Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders
This phase II trial studies the side effects and best dose of total-body irradiation when given together with fludarabine phosphate followed by a donor peripheral stem cell transplant in treating patients with myelodysplastic…
- Conditions
- Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Essential Thrombocythemia
- Trial name
- NCT00397813
- Testing
- Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 77 people
- Sponsor
- Fred Hutchinson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.